Literature DB >> 24995234

Efficacy of Tranexamic Acid in Reducing Blood Loss during Maxillofacial Trauma Surgery-A Pilot Study.

Abu Dakir1, Balakrishnan Ramalingam2, Vijay Ebenezer2, Prakash Dhanavelu1.   

Abstract

PURPOSE: Tranexamic acid (TXA) is prescribed for short term management of haemorrhage. It is also administered prophylatically in surgeries where blood loss is anticipated. Tranexamic mouth washes are also used in oral surgical procedures for patients with coagulopathies. The purpose of this study was to assess the efficiency of the usage of tranexamic acid on reduction of haemorrhage in maxillo mandibular trauma cases.
MATERIALS AND METHODS: Twelve consecutive male patients, between the ages 20-40 years, with multiple fractures of the facial bones, were included in this study. Six patients were administered either IV tranexamic acid (10 mg/kg- Group 1)and another six placebo (IV normal saline- Group 2) just before induction of anaesthesia. All patients were operated by the same surgical team, using the same standard techniques and the same anaesthetist and the same drugs were used during the surgery. Hypotension was induced for further reduction of intra operative blood loss. Intra and post-operative blood loss, operation time, transfusion of blood products, pre- and post-operative haemoglobin, number of days of hospitalisation and blood count were recorded for both groups.
RESULTS: Tranexamic acid significantly reduced the volume of blood loss during the surgery when compared with the control group (489.17± 106.7 mL vs 900.83 ± 113.7 mL). Considering the duration of operation and the treatment groups only, the mean total blood loss in the control group was 411.67 mL more than that in the tranexamic acid group. None of the patients of the TXA group required blood transfusion post-operatively. There was no difference in the length of hospital stay between the 2 groups. Two of the patients of the saline group required blood transfusion post-surgery due to significant drop in haemoglobin. The average drop in haemoglobin was 2 ± 1.4 in the tranexamic group and 4 ± 1.09 in the saline group.
CONCLUSION: Pre-operative intravenous bolus administration of tranexamic acid at 10 mg/kg reduces blood loss compared with placebo during the surgery.

Entities:  

Keywords:  Haemorrhage; Normal saline (NS); Surgery; Tranexamic acid (TXA)

Year:  2014        PMID: 24995234      PMCID: PMC4080055          DOI: 10.7860/JCDR/2014/8680.4313

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  28 in total

1.  Blood loss after total hip replacement: a prospective randomized study between wound compression and drainage.

Authors:  Torsten Johansson; Markus Engquist; Lars-Göran Pettersson; Björn Lisander
Journal:  J Arthroplasty       Date:  2005-12       Impact factor: 4.757

2.  Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers.

Authors:  O Eriksson; H Kjellman; A Pilbrant; M Schannong
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

3.  Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants.

Authors:  G Ramström; S Sindet-Pedersen; G Hall; M Blombäck; U Alander
Journal:  J Oral Maxillofac Surg       Date:  1993-11       Impact factor: 1.895

Review 4.  Clinical application of inhibitors of fibrinolysis.

Authors:  M Verstraete
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

5.  The effect of tranexamic acid on blood loss during orthognathic surgery: a randomized controlled trial.

Authors:  Wing Shan Choi; Michael G Irwin; Nabil Samman
Journal:  J Oral Maxillofac Surg       Date:  2009-01       Impact factor: 1.895

6.  Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study.

Authors:  Glen Carter; Alastair Goss; John Lloyd; Ric Tocchetti
Journal:  J Oral Maxillofac Surg       Date:  2003-12       Impact factor: 1.895

7.  Maxillofacial trauma: a potentially fatal injury.

Authors:  S R Thaller; S L Beal
Journal:  Ann Plast Surg       Date:  1991-09       Impact factor: 1.539

8.  Pharmacokinetics and bioavailability of tranexamic acid.

Authors:  A Pilbrant; M Schannong; J Vessman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Life-threatening bleeding following maxillofacial trauma.

Authors:  L Ardekian; N Samet; Y Shoshani; S Taicher
Journal:  J Craniomaxillofac Surg       Date:  1993-12       Impact factor: 2.078

10.  Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study).

Authors: 
Journal:  BMJ       Date:  2011-07-01
View more
  5 in total

Review 1.  Tranexamic acid: from trauma to routine perioperative use.

Authors:  Jeff Simmons; Robert A Sikorski; Jean-Francois Pittet
Journal:  Curr Opin Anaesthesiol       Date:  2015-04       Impact factor: 2.706

Review 2.  Tranexamic Acid in Orthopaedic Trauma Surgery: A Meta-Analysis.

Authors:  Elizabeth B Gausden; Rameez Qudsi; Myles D Boone; Brian OʼGara; Joseph J Ruzbarsky; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2017-10       Impact factor: 2.512

3.  Impact of Aprotinin - A Proteolytic Enzyme on Postsurgical Symptoms in Patients Undergoing Third Molar Surgeries.

Authors:  Visakan Jegadeesan; Deepa Ponnaiyan
Journal:  J Clin Diagn Res       Date:  2016-01-01

4.  Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Isabel Taeuber; Stephanie Weibel; Eva Herrmann; Vanessa Neef; Tobias Schlesinger; Peter Kranke; Leila Messroghli; Kai Zacharowski; Suma Choorapoikayil; Patrick Meybohm
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

5.  Role of Local Infiltration of Tranexamic Acid in Reducing Blood Loss in Peritrochanteric Fracture Surgery in the Elderly Population.

Authors:  S R Virani; A A Dahapute; I Panda; S S Bava
Journal:  Malays Orthop J       Date:  2016-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.